Physician profile
Alejandro Torres
NPI 1053852491
$1,872.57
in general payments reported to CMS, 2019-2025
25 companies · $425 in 2025
The $425 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $79.26 · 2021: $377 · 2022: $326 · 2023: $450 · 2024: $215 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $525.23 | 2021-2025 | Azstarys |
| Tris Pharma INC | $308.76 | 2020-2025 | Dyanavel Xr |
| Cranial Technologies, INC | $144.54 | 2020-2025 | Doc Band |
| Pfizer INC. | $135.42 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.06 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $76.39 | 2024-2025 | |
| Glaxosmithkline, LLC. | $59.74 | 2020-2023 | Pediarix, Bexsero |
| Ars Pharmaceuticals Operations, INC. | $59.58 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $58.54 | 2021-2024 | Gardasil 9, Gardasil, M-M-R II |
| Ironshore Pharmaceuticals INC. | $55.85 | 2022-2023 | Jornay Pm |
| Kaleo, INC. | $47.54 | 2021-2023 | Auvi-Q |
| Adlon Therapeutics L.P. | $42.83 | 2020-2021 | |
| Seqirus USA INC | $41.12 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Allegis Pharmaceuticals, LLC | $29.10 | 2022-2023 | Spinosad |
| Lnhc, INC | $23.44 | 2025 | Zelsuvmi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $23.39 | 2021 | |
| Hologic Sales and Service, LLC | $21.08 | 2022 | |
| Supernus Pharmaceuticals, INC. | $20.05 | 2021 | |
| Sobi, INC | $19.57 | 2023 | |
| Abbvie INC. | $17.98 | 2022 | |
| Neos Therapeutics, Lp | $15.20 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.00 | 2023 | Koselugo |
| Genentech USA, INC. | $14.76 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.60 | 2025 | Jornay Pm |
| Bavarian Nordic A/S | $13.80 | 2025 | Vivotif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.